Abstract: Fusion proteins include an extracellular domain of PD1 protein (programmed cell death protein-1) and/or an extracellular domain of PD-L1 protein (programmed cell death-ligand 1 protein (CD274 or B7-H1)). Portions of the extracellular domains are expressed in specific configurations and purified as protein, which are used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. A method is for determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient when the patient has undergone at least one dose of immunotherapy.

Abstract: Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.

Abstract: A lateral flow immunoassay for the detection of anti-drug antibodies against a biological drug includes a membrane having a capture area, a sample application area, a flow path from the sample application area to the capture area, and a conjugate area located in the flow path. The conjugate area has said biological drug detectably labeled and the capture area has said biological drug immobilized thereto.

Abstract: A lateral flow immunoassay for the detection of anti-drug antibodies against a biological drug includes a membrane having a capture area, a sample application area, a flow path from the sample application area to the capture area, and a conjugate area located in the flow path. The conjugate area has said biological drug detectably labeled and the capture area has said biological drug immobilized thereto.

Abstract: Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.

Abstract: The invention relates to the field of personalized therapy and, in particular, to a method for classifying a patient suffering from rheumatoid arthritis as a responder or as a non-responder patient to a treatment based on a biological drug.

Abstract: The invention relates to the field of personalized therapy and, in particular, to a method for classifying a patient suffering from rheumatoid arthritis as a responder or as a non-responder patient to a treatment based on a biological drug.

Abstract: The invention relates to the field of personalized therapy and, in particular, to a method for classifying a patient suffering from rheumatoid arthritis as a responder or as a non-responder patient to a treatment based on a biological drug.

Abstract: The present invention refers to a group of biomarkers and to non-invasive in vitro methods for the diagnosis or prognosis of endometriosis, as well as to a kit to perform said methods.